Adaltis receives notification of approval from the SFDA for the sale of Eclectica(TM) in China

    MONTREAL, April 24 /CNW Telbec/ - Adaltis Inc. (TSX: ADS), an
international in vitro diagnostic (IVD) company, today announced that it has
received notification of approval by the SFDA (State Food and Drug
Administration, P.R. China) for the sale of its flagship product Eclectica(TM)
in China. Adaltis expects to initiate the commercialization of Eclectica(TM)
in China over the next few weeks.
    "We are very excited about this milestone for Adaltis. China is the
primary market for Adaltis, and we believe that our Eclectica(TM) benchtop
instrument is ideally suited for the needs of small to medium-sized
laboratories and hospitals in the Chinese market. We intend to initiate the
commercialization of Eclectica(TM) within the month of May 2007," said
Dr. Raymond Tong, Chief Operating Officer of Adaltis.

    About Eclectica(TM)

    Eclectica(TM) is a benchtop hybrid analyzer allowing for the
consolidation of automation platforms in clinical labs. Eclectica(TM) combines
into a compact, single workstation the ability to perform Immunoassay,
Clinical Chemistry and Plasma Protein tests. It is aimed at small to
medium-sized clinics and laboratories that require low to medium workloads of
particular tests.
    The flat touch-screen color monitor along with the separate
alphanumerical keyboard provides the user with a friendly and fast interface
with the instrument. Eclectica(TM) can be connected with a Laboratory
Information System to directly download and upload data.

    About Adaltis

    Adaltis is an international in vitro diagnostic company that develops,
manufactures and markets diagnostic systems. It aims to leverage its
experience in Europe to become a leading provider of in vitro diagnostic
products in emerging markets, with a particular focus on China.
    With the assistance of its two strategic shareholders, CITIC Pacific
Limited (a large Hong Kong-based conglomerate) and Picchio Pharma Inc. (a
joint venture healthcare investment firm owned by FMRC Family Trust (a trust
of which Dr. Francesco Bellini is a beneficiary), and Power Technology
Investment Corporation, a subsidiary of Power Corporation of Canada), Adaltis
has completed building its manufacturing facility in Shanghai. Now
operational, the production facility manufactures high-quality products in a
low-cost GMP environment, in order to service existing markets in Europe,
while providing a platform to penetrate the high-growth Chinese in vitro
diagnostic market.
    Adaltis is headquartered in Montreal, with offices in China, Hong Kong,
Italy, Germany and Mexico.

    Caution Concerning Forward-Looking Statements

    Certain statements made in this press release, including in particular
the impact of the SFDA approval, our ability to make sales in the Chinese
market, and other anticipated market opportunities for our Eclectica(TM)
instrument, are forward-looking statements and are subject to important risks,
uncertainties and assumptions. The Company cautions that, by their nature,
forward-looking statements involve risk and uncertainty and the Company's
actual actions or results could differ materially from those expressed or
implied in such forward-looking statements. The forward-looking statements
contained in this press release represent the expectations of Adaltis Inc. and
its subsidiaries as at the date hereof and accordingly are subject to change
after such date. However, Adaltis Inc. and its subsidiaries expressly disclaim
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by applicable law.
    For additional information with respect to the risks and uncertainties
and other factors that could cause the results or events predicted in these
forward-looking statements to differ materially from actual results or events,
please refer to the Annual Information Form of the Company filed with the
Canadian securities commissions.

For further information:

For further information: Jacques Deforges, Vice President, Finance and
Chief Financial Officer, Adaltis Inc., (514) 335-9922, ext. 245,; Eddy Miller, Director, Investor Relations,
Adaltis Inc., (514) 335-9922, ext. 257,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890